On the contrary, a 32-years-old female MS patient with self-limiting COVID-19 disease, developing approximately four weeks after treatment course, showed negative IgM and IgG anti- SARS-CoV-2 antibodies one month after the infection [85], similarly to a case described by Preziosa et al. [84]. The gene discussed is CD40LG; the disease is myeloid sarcoma.